

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Mai, HK;Trieu, NB;Long, TH;Thanh, HT;Luong, ND;Huy, LX;Nguyet, LA;Huy Man, DN;Anderson, DE;Thanh, TT;van Vinh Chau, N;Thwaites, G;Wang, LF;Le Van Tan,;Hung, DT

Title:

Long-term humoral immune response in persons with asymptomatic or mild SARS-CoV-2 infection, Vietnam

Date:

2021-02-01

Citation:

Mai, H. K., Trieu, N. B., Long, T. H., Thanh, H. T., Luong, N. D., Huy, L. X., Nguyet, L. A., Huy Man, D. N., Anderson, D. E., Thanh, T. T., van Vinh Chau, N., Thwaites, G., Wang, L. F., Le Van Tan, & Hung, D. T. (2021). Long-term humoral immune response in persons with asymptomatic or mild SARS-CoV-2 infection, Vietnam. *Emerging Infectious Diseases*, 27 (2), pp.663-666. <https://doi.org/10.3201/eid2702.204226>.

Persistent Link:

<https://hdl.handle.net/11343/278691>

License:

CC BY

analyzed (e.g., brain, liver, spleen, kidney, small and large intestine, heart, and eyelids). These results suggest that virus infection by natural transmission between cats, as well as by experimental inoculation, induces protective immunity against a second SARS-CoV-2 infection.

In conclusion, SARS-CoV-2 replicated effectively in the upper respiratory tract in cats, and infectious virus was cleared from the lungs within 6 days of infection; however, histopathologic examination demonstrated chronic lung sequelae in cats even a month after viral clearance. After initial infection with SARS-CoV-2, cats were protected from reinfection, with no virus replication in respiratory organs and no additional lung damage.

Acknowledgment

We thank Gillian McLellan for the cats used in this study and Sue Watson for scientific editing. We would also like to thank Angela Brice and Olga Gonzalez for sharing their expertise with our pathologists during consultation as well as Amanda Novak, Emily Tran, and Sara Stuedemann for their technical support.

This research was supported by the Center for Research on Influenza Pathogenesis, funded by the National Institutes of Allergy and Infectious Diseases, National Institutes of Health (grant no. HHSN272201400008C awarded to Y.K.); the Research Program on Emerging and Re-emerging Infectious Disease from Japan Agency for Medical Research and Development (AMED) (grant no. JP19fk0108113 awarded to Y.K.); the Japan Initiative for Global Research Network on Infectious Diseases from AMED (grant no. JP19fm0108006 awarded to Y.K.); the Japan Program for Infectious Diseases Research and Infrastructure from AMED (grant no. JP20wm0125002 to Y.K.); and a University of Wisconsin K12 Career Development Award from the National Institute of Diabetes and Digestive and Kidney Diseases (grant no. K12DK100022 awarded to L.K.C.).

About the Author

Dr. Chiba is a molecular virologist at the Influenza Research Institute at the University of Wisconsin–Madison, with a background in innate immunity studies and structural biology. Her primary research interests include mechanisms of virus infection, virus antigenicity, and host immune responses.

References

1. Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, et al. Transmission of SARS-CoV-2 in domestic cats. *N Engl J Med*. 2020;383:592–4. <https://doi.org/10.1056/NEJMc2013400>

2. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science*. 2020;368:1016–20. <https://doi.org/10.1126/science.abb7015>
3. Cheung OY, Chan JW, Ng CK, Koo CK. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). *Histopathology*. 2004;45:119–24. <https://doi.org/10.1111/j.1365-2559.2004.01926.x>
4. Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian J Radiol Imaging*. 2017;27:342–9. https://doi.org/10.4103/ijri.IJRI_469_16
5. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med*. 2020;383:120–8. <https://doi.org/10.1056/NEJMoa2015432>

Address for correspondence: Yoshihiro Kawaoka, 575 Science Dr, Madison, Wisconsin 53711, USA; email: yoshihiro.kawaoka@wisc.edu; or LaTasha K. Crawford, 2015 Linden Dr, Madison, Wisconsin 53706, USA; email: lkrcrawford@wisc.edu

Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam

Huynh Kim Mai, Nguyen Bao Trieu, Trinh Hoang Long, Hoang Tien Thanh, Nguyen Dinh Luong, Le Xuan Huy, Lam Anh Nguyet, Dinh Nguyen Huy Man, Danielle E. Anderson, Tran Tan Thanh, Nguyen Van Vinh Chau, Guy Thwaites, Lin-Fa Wang, Le Van Tan, Do Thai Hung

Author affiliations: Pasteur Institute, Nha Trang City, Vietnam (H.K. Mai, N.B. Trieu, T.H. Long, H.T. Thanh, N.D. Luong, L.X. Huy, D.T. Hung); Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (L.A. Nguyet, T.T. Thanh, G. Thwaites, L.V. Tan); Hospital for Tropical Diseases, Ho Chi Minh City (D.N.H. Man, N.V.V. Chau); Duke-NUS Medical School, Singapore (D.E. Anderson, L.-F. Wang); Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK (G. Thwaites); SingHealth Duke-NUS Global Health Institute, Singapore (L.-F. Wang)

DOI: <https://doi.org/10.3201/eid2702.204226>

Antibody response against nucleocapsid and spike proteins of SARS-CoV-2 in 11 persons with mild or asymptomatic infection rapidly increased after infection. At weeks 18–30 after diagnosis, all remained seropositive but spike protein–targeting antibody titers declined. These data may be useful for vaccine development.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease (COVID-19) pandemic (1). Effective vaccines are vital for mitigating the impact of the pandemic. As such, synthesizing a long-term humoral immune response to SARS-CoV-2 remains essential to developing and implementing a SARS-CoV-2 vaccine. We report a longitudinal study of 11 persons with SARS-CoV-2 infection in Vietnam, in which we monitored antibody responses for up to 30 weeks after infection.

We included patients with a confirmed SARS-CoV-2 infection admitted to a COVID-19 treatment center in central Vietnam during January–March 2020. To enable long-term follow-up, we excluded all short-term visitors. We collected information from each participant about clinical status, travel history, contacts with persons with confirmed cases, and personal demographics. For plasma collection, we applied a flexible sampling schedule encompassing 30 weeks after diagnosis, stratified by collection at 1, 2–3, 4–7, and ≥18 weeks after diagnosis.

We measured antibodies against 2 main immunogens of SARS-CoV-2, the nucleocapsid (N) and spike (S) proteins, by using 2 well-validated sensitive and specific serologic assays, Elecsys Anti-SARS-CoV-2

assay (Roche, <https://diagnostics.roche.com>) (2) and SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) (GenScript, <https://www.genscript.com>) (3). The former is an electrochemiluminescence immunoassay that uses recombinant N protein for qualitative detection of pan Ig, including IgG, against SARS-CoV-2. The latter is a surrogate assay for measuring receptor-binding domain–targeting neutralizing antibodies (RBD-targeting NABs) (3,4), in principle a blocking ELISA that quantifies antibodies that block the receptor–RBD interaction (3). Our study forms part of the national COVID-19 response and was approved by the institutional review board of the Pasteur Institute in Nha Trang, Vietnam.

During the study period, there were a total of 23 patients with confirmed SARS-CoV-2 infection in central Vietnam. Ten were tourists and were thus excluded from the study. Of the remaining 13, a total of 11 consented to participate in this study. Among study participants, 6 were female and 5 were male; the age range was 12–64 years (Table). Seven experienced mildly symptomatic infection and did not require supplemental oxygen during hospitalization; 4 were asymptomatic. Before becoming ill, 3 had traveled to a SARS-CoV-2–endemic country, including patients 2 and 3, who had traveled to Malaysia and patient 4 had traveled to the United States. Patient 4 transmitted the virus to 6 of her contacts, including 4 family members and 2 employees. Of these, 2 transmitted the virus to another family member (Table; Appendix Figure, <https://wwwnc.cdc.gov/EID/article/27/2/20-4226-App1.pdf>).

Table. Demographics, travel history, contact history, clinical status, and outcome for participants in study of long-term humoral immune response in persons with asymptomatic or mild SARS-CoV-2 infection, Vietnam, 2020*

Patient no.†	Age, y/sex	Province	Presumed exposure	Symptoms developed	Diagnosed	Presumed incubation period, d	Recent travel history	Contact with confirmed patient	Clinical status	Hospital stay, d
1	25/F	Khanh Hoa	Jan 14	Jan 18	Jan 24	4	None	1 of first 2 cases in Vietnam	Sympt	11
2	42/M	Ninh Thuan	Feb 27–Mar 4	Mar 9	Mar 16	5–14	Malaysia	Unknown	Sympt	16
3	36/M	Ninh Thuan	Feb 27–Mar 4	Mar 13	Mar 17	9–15	Malaysia	Unknown	Sympt	15
4	51/F	Binh Thuan	Feb 22–29	Mar 5	Mar 9	7–14	USA	Unknown	Sympt	25
5‡	51/M	Binh Thuan	Mar 2–9	Mar 11	Mar 11	2–9	None	Husband of patient 4	Sympt	23
6‡	64/F	Binh Thuan	Mar 2–10	Asympt	Mar 10	5–8	None	Domestic worker of patient 4	Asympt	31
7‡	28/F	Binh Thuan	Mar 7	Asympt	Mar 10	3	None	Daughter-in-law of patient 4	Asympt	24
8‡	28/M	Binh Thuan	Mar 2–9	Mar 11	Mar 11	2–9	None	Son of patient 4	Sympt	23
9‡	47/F	Binh Thuan	Mar 3–8	Mar 11	Mar 11	3–8	None	Mother of patient 7	Sympt	23
10‡	37/F	Binh Thuan	Mar 3–8	Asympt	Mar 10	2–7	None	Staff of patient 4	Asympt	24
11‡	12/M	Binh Thuan	Mar 3–8	Asympt	Mar 11	2–7	None	Son of patient 10	Asympt	30

*All patients made a full recovery. No patients required oxygen. All patients were of Vietnamese nationality. First enrollment was on January 24, 2020, and last was on March 17, 2020. Last follow up was on August 13, 2020. Asympt, asymptomatic; sympt, symptomatic.


†Patient numbers match those in Figure 1.

‡Patients from a cluster involving 3 household transmission chains (Appendix Figure, <https://wwwnc.cdc.gov/EID/article/27/2/20-4226-App1.pdf>).

Figure. Antibody responses in 11 study participants, weeks 1–20 after PCR diagnosis of SARS-CoV-2 infection, Vietnam, 2020.

A) Seroprevalence of SARS-CoV-2 among 11 COVID-19 patients. We followed testing protocols and the positive cutoff of 20% recommended in the Elecsys Anti-SARS-CoV-2 assay (Roche, <https://diagnostics.roche.com>) without any modification. Using these parameters, previous studies showed an excellent concordance between results from surrogate virus neutralization tests

and conventional neutralizing antibody detection assays (3,4). Vertical bars denote 95% CIs. Graphs were created using GraphPad Prism version 8.0 (GraphPad software, <https://www.graphpad.com>). B) Kinetics of neutralizing antibodies measured by the surrogate neutralization assay (GenScript, <https://www.genscript.com>) with the 20% cutoff applied. We tested samples at 1:10 dilution as specified. Because of the limited availability of plasma samples, each sample was tested only once. RBD, receptor-binding domain; NAbs, neutralizing monoclonal antibodies; S, spike; N, nucleocapsid.



We collected 43 plasma samples from 11 participants within 4 time ranges after diagnosis: <1 week ($n = 10$), weeks 2–3 ($n=11$), weeks 4–7 ($n=11$), and weeks 18–30 ($n = 11$). During the first week after diagnosis, 1 patient (1/10, 10%) had detectable RBD-targeting NAbs, and none had antibodies against N protein. In subsequent weeks, all (100%) participants tested positive by surrogate virus neutralization. Antibodies against N protein were detected in 10/11 (91%) of the samples collected between the second and third weeks after diagnosis and 11/11 (100%) samples collected at subsequent time points (Figure, panel A).

Previous studies have demonstrated that the inhibition percentage measured by surrogate virus neutralization tests correlates well with neutralizing antibody titers measured by conventional virus neutralization assays or plaque-reduction neutralization tests (3,4). In our study, the inhibition percentage was below the assay cutoff in all but 1 plasma sample taken during the first week after diagnosis and then rapidly increased above the assay cutoff at subsequent time points. At weeks 18–30 after diagnosis, the inhibition percentage declined but remained detectable (Figure, panel B).

We demonstrate that antibodies against 2 main structural proteins (S and N) of SARS-CoV-2 in patients with asymptomatic or mild infections were almost undetectable within the first week after diagnosis. Antibodies rapidly increased in subsequent weeks and peaked around weeks 4–7 before declining during the later phase of infection, consistent with previously reported findings (2,5–7). However, few studies have reported the persistence of long-term

humoral immune response to SARS-CoV-2 up to 18–30 weeks after diagnosis (5), especially among mildly symptomatic or asymptomatic infected patients.

The titers of RBD-targeting NAbs, which are well correlated with those of neutralizing antibodies, decayed by weeks 18–30 after infection, suggesting that humoral immunity to SARS-CoV-2 infection may not be long lasting. Because neutralizing antibodies are recognized as a surrogate for protection (7–9), follow-up studies beyond this period are needed to more conclusively determine the durability of these long-term responses and their correlation with protection.

Our collective findings offer insights into the long-term humoral immune response to SARS-CoV-2 infection. The data might have implications for COVID-19 vaccine development and implementation and other public health responses to the COVID-19 pandemic.

Acknowledgments

We thank the patients for their participations in this study and the diagnostic team at the Hospital for Tropical Diseases, Le Nguyen Truc Nhu, Nguyen Thi Thu Hong for laboratory support.

This study was funded by the World Health Organization and the US Centers for Disease Control and Prevention through the Field Epidemiology of Training Programmes. L.V.T. and G.T. are supported by the Wellcome Trust of Great Britain (204904/Z/16/Z and 106680/B/14/Z, respectively). The serology work at Duke-NUS is supported by grants from the National Medical Research Council, Singapore (STPRG-FY19-001 and COVID19RF-003).

About the Author

Ms. Mai is vice-head of the virology department of the Pasteur Institute in Nha Trang City, Vietnam. She has been part of a team responsible for COVID-19 diagnostics in an area of central Vietnam with a population of ≈ 25 million people.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.; for the China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727–33. <https://doi.org/10.1056/NEJMoa2001017>
2. Chen SY, Lee YL, Lin YC, Lee NY, Liao CH, Hung YP, et al. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. *Emerg Microbes Infect*. 2020;9:2157–68. <https://doi.org/10.1080/22221751.2020.1825016>
3. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol*. 2020;38:1073–8. <https://doi.org/10.1038/s41587-020-0631-z>
4. Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera. *J Clin Microbiol*. 2020;JCM.02504-20. <https://doi.org/10.1128/JCM.02504-20>
5. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. *N Engl J Med*. 2020;383:1724–34. <https://doi.org/10.1056/NEJMoa2026116>
6. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. *Emerg Microbes Infect*. 2020;9:940–8. <https://doi.org/10.1080/22221751.2020.1762515>
7. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.; on behalf of the Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396:467–78. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4)
8. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature*. 2020;586:578–82. <https://doi.org/10.1038/s41586-020-2608-y>
9. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science*. 2020;369:818–23. <https://doi.org/10.1126/science.abc5343>

Address for correspondence: Huynh Kim Mai, 8-9-10 Tran Phu, Xuong Huan Ward, Nha Trang City, Khanh Hoa Province, Vietnam; email: mai064@yahoo.com and Le Van Tan, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam; email: tanlv@oucru.org

Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020

Sitanshu Sekhar Kar, Sonali Sarkar, Sharan Murali, Rahul Dhodapkar, Noyal Mariya Joseph, Rakesh Aggarwal

Author affiliation: Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

DOI: <https://doi.org/10.3201/eid2702.204480>

We conducted 3 population-based cross-sectional surveys, at 1-month intervals, to estimate the prevalence and time-trend of severe acute respiratory syndrome coronavirus 2 infection in Puducherry, India. Seropositivity rate increased from 4.9% to 34.5% over 2 months and was 20-fold higher than the number of diagnosed cases of infection.

The magnitude of the ongoing pandemic of coronavirus disease (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not been fully assessed because most those infected have no or mild symptoms, and thus do not undergo viral nucleic acid or antigen testing (1–3). Determining the proportion of a population that has had infection at various time points is essential for understanding the dynamics of an epidemic in a particular area.

Puducherry district, population ≈ 1.25 million, is located in southern India. Its earliest recorded case of COVID-19 was in March 2020; it had 7 total cases by the end of May, 67 by end of June, and 663 by end of July 2020 (4). The district followed national COVID-19 management guidelines, including testing all symptomatic persons and their high-risk contacts.

We conducted 3 community-based serologic surveys for SARS-CoV-2 antibodies in Puducherry at 1-month intervals, i.e., during August 11–16, September 10–16, and October 12–16, 2020 (Figure). Each survey included 900 adults selected using a multistage sampling procedure. In the initial stages, we chose 30 clusters, including 21 of 90 urban wards and 9 of 62 villages, using a probability proportional to size with replacement method; this method replicated the urban-to-rural ratio (70:30) of the district's population. Thereafter, in each cluster, we chose 30 households by systematic random sampling; we collected blood from 1 adult (≥ 18 years of age) in each household using a modified Kish method (5,6). The data from these surveys represent the cumulative proportion of